UA138934U - METHOD FOR PREDICTING THE DEVELOPMENT OF OSTEOARTHRITIS - Google Patents

Abstract

The method of predicting the development of osteoarthritis includes clinical examination and radiography. Additionally, in the patient's serum determine the polymorphism of the nitric oxide synthase gene (eNOS T786C), the content of endothelin, folic acid, pyridinoline, transforming growth factor beta 1 (TGF-b1), homocysteine, C-reactive protein (SRP). With a homozygous carrier of 786-CC, levels of endothelin> 10 ng / ml, folic acid <6 ng / ml, pyridinoline> 8 ng / ml, TGF-b1 <14 ng / ml, homocysteine> 20 μmol / l, PSA> 6 mg / l predict the development of osteoarthritis.

Description

The proposed useful model The method of predicting the development of osteoarthritis belongs to medicine, in particular to orthopedics and rheumatology. It is prescribed and can be used in diagnosing the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include x-rays, studies of biopsies of the synovial membrane, synovial fluid, and cartilage biopsies (Okorokov

A.N. Diagnosis of diseases of internal organs. - M., 2001. - Vol. 2. - P. 186-196). The disadvantage of these methods is the lack of the possibility of predicting the dynamics of the process in the early subclinical stages, preventing its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The task is solved by the fact that, in addition to clinical examination and radiography, the polymorphism of the nitric oxide synthase gene (eMO5 1786C), the content of endothelin, folic acid, pyridinoline, transforming growth factor beta 1 (TGF-DI1), homocysteine, C are determined in the patient's blood serum -reactive protein (SRP) and with homozygous carrier 786-SS, levels of endothelin 210 ng/ml, folic acid "6 ng/ml, pyridinoline "8 ng/ml, TGF-B1" 14 ng/ml, homocysteine 220 μmol/l , SRP»E mg/l predict the development of osteoarthritis.

Application of the method. During hospitalization, the patient is examined, x-rays are taken, the polymorphism of the eMmo5 1786C gene is determined, the content of endothelin, folic acid, pyridinoline, TFR-DV1, homocysteine, SRP is determined by the immunoenzymatic method. With homozygous carrier 786-

SS and levels of endothelin 210 ng/ml, folic acid "6 ng/ml, pyridinoline 8 ng/ml, TFR-VD1 "14 ng/ml, homocysteine 220 μmol/l, SRP "6 mg/l predict the development of osteoarthritis.

A specific example of using the method

Patient K., 59 years old, was hospitalized in the clinic due to pain syndrome in the left knee joint. Examined, x-ray taken. No signs of osteoarthritis were found. The eMO5 1786C gene polymorphism and the content of endothelin, folic acid, pyridinoline, TFR-B1I, homocysteine, SRP were determined in the blood serum. A homozygous carrier of 786-SS was established, levels of endothelin - 22 ng/ml, folic acid - 2.9 ng/ml, pyridinoline - 16 ng/ml, TGF-B1-7.5 ng/ml, homocysteine - 40 μmol/l, SRP - 17 mg/l.

The development of osteoarthritis was diagnosed. After 12 months, X-rays revealed signs of osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Claims (1)

USEFUL MODEL FORMULA The method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, which differs in that the polymorphism of the nitric oxide synthase gene (eMmO5 17860), the content of endothelin, folic acid, pyridinoline, transforming growth factor beta 1 (TGF-RI), homocysteine, C-reactive protein (CRP) is additionally determined in the patient's blood serum. with homozygous carrier 786-SS, levels of endothelin 210 ng/ml, folic acid "6 ng/ml, pyridinoline "8 ng/ml, TFR-DRI "14 ng/ml, homocysteine 220 μmol/l, SRP "6b mg/l predict the development of osteoarthritis.